| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
| Targets |
Toluidine Blue does not target a specific protein or enzyme. Its utility in histological staining is based on its metachromatic properties and its ability to bind to acidic tissue components through electrostatic interactions.
|
|---|---|
| ln Vitro |
The in vitro activity of Toluidine Blue is its ability to stain biological tissues metachromatically. The dye binds to acidic tissue components such as mast cell granules, cartilage, and mucopolysaccharides, producing color changes that enable the visualization of these structures under a microscope.
|
| ln Vivo |
Toluidine Blue is not used as a systemic therapeutic agent. However, it is used in diagnostic procedures, including the detection of dysplasia in oral and cervical tissues and in sentinel lymph node mapping. The dye is applied topically or locally for these diagnostic applications.
|
| Enzyme Assay |
In vitro binding assays are not applicable for Toluidine Blue as it functions as a histological dye rather than a drug targeting specific enzymes or receptors. The compound is used in staining protocols where it is applied directly to tissue sections or cellular samples.
|
| Cell Assay |
For in vitro cellular experiments, Toluidine Blue is used in histological staining procedures. Tissue sections or cellular samples are incubated with the dye solution, and after appropriate washing steps, the stained samples are examined under a microscope. The metachromatic properties of the dye provide contrast for the visualization of specific tissue components.
|
| Animal Protocol |
For in vivo animal experiments, Toluidine Blue may be used in diagnostic procedures such as sentinel lymph node mapping. The dye is administered locally to visualize lymphatic drainage and identify sentinel lymph nodes.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Toluidine Blue have not been extensively characterized. The compound is used topically or locally for diagnostic applications. Systemic absorption is minimal when used appropriately.
|
| Toxicity/Toxicokinetics |
Toxicological data for Toluidine Blue indicates that it is generally well-tolerated when used for diagnostic staining. However, as with all dyes, there is potential for hypersensitivity reactions. The compound is not intended for systemic therapeutic use.
|
| References |
[1]. Sridharan G, et al. Toluidine blue: A review of its chemistry and clinical utility. J Oral Maxillofac Pathol. 2012;16(2):251-255.
|
| Additional Infomation |
Toluidine chloride is an organochloride with the counterion 3-amino-7-(dimethylamino)-2-methylphenothiazine-5-onium (toluidine). It is a blue nuclear counterstain used to visualize Nissl bodies and to stain mast cell granules in metachromatic and orthochromatic staining techniques. It is also used as a fluorescent dye, histological dye, and diagnostic reagent. It contains toluidine. Phenothiazine has been used as a hemostatic agent, biological stain, and dye for wool and silk. Toluidine chloride has also been used in the auxiliary diagnosis of oral and gastric tumors, and for the identification of parathyroid glands during thyroid surgery. See also: Toluidine Blue (note moved to).
Pharmacological Indications Treatment of dental and oral soft tissue infections. Toluidine Blue O is a basic thiazine metachromatic dye widely used in histology and pathology for staining mast cell granules, cartilage, and other acidic tissue components. The compound has no clinical or therapeutic applications and has not received regulatory approval for systemic use. |
| Molecular Formula |
C15H16CLN3S
|
|---|---|
| Molecular Weight |
305.83
|
| Exact Mass |
305.075
|
| CAS # |
92-31-9
|
| Related CAS # |
Toluidine Blue (purity 36%)
|
| PubChem CID |
7083
|
| Appearance |
Green to dark green solid powder
|
| LogP |
1.272
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
20
|
| Complexity |
512
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[Cl-].N1C2C(=CC(=C(C)C=2)N)[S+]=C2C=1C=CC(N(C)C)=C2
|
| InChi Key |
GEDVVYWLPUPJJZ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H15N3S.ClH/c1-9-6-13-15(8-11(9)16)19-14-7-10(18(2)3)4-5-12(14)17-13;/h4-8,16H,1-3H3;1H
|
| Chemical Name |
(7-amino-8-methylphenothiazin-3-ylidene)-dimethylazanium;chloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 20.83 mg/mL (68.11 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2698 mL | 16.3490 mL | 32.6979 mL | |
| 5 mM | 0.6540 mL | 3.2698 mL | 6.5396 mL | |
| 10 mM | 0.3270 mL | 1.6349 mL | 3.2698 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Link: https://clinicaltrials.gov/ct2/show/NCT07266233
Conditions:Root Canal InfectionLink: https://clinicaltrials.gov/ct2/show/NCT03264118
Conditions:Periodontitis, Chronic|Periodontal Diseases|Periodontal Bone LossProducts are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
